...
首页> 外文期刊>Brain pathology >p14ARF deletion and methylation in genetic pathways to glioblastomas.
【24h】

p14ARF deletion and methylation in genetic pathways to glioblastomas.

机译:胶质母细胞瘤遗传途径中的p14ARF缺失和甲基化。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The CDKN2A locus on chromosome 9p21 contains the p14ARF and p16INK4a genes, and is frequently deleted in human neoplasms, including brain tumors. In this study, we screened 34 primary (de novo) glioblastomas and 16 secondary glioblastomas that had progressed from low-grade diffuse astrocytomas for alterations of the p14ARF and p16INK4a genes, including homozygous deletion by differential PCR, promoter hypermethylation by methylation-specific PCR, and protein expression by immunohistochemistry. A total of 29 glioblastomas (58%) had a p14ARF homozygous deletion or methylation, and 17 (34%) showed p16INK4a homozygous deletion or methylation. Thirteen glioblastomas showed both p14ARF and p16INK4a homozygous deletion, while nine showed only a p14ARF deletion. Immunohistochemistry revealed loss of p14ARF expression in the majority of glioblastomas (38/50, 76%), and this correlated with the gene status, i.e. homozygous deletion or promoter hypermethylation. There was no significant difference in the overall frequency of p14ARF and p16INK4a alterations between primary and secondary glioblastomas. The analysis of multiple biopsies from the same patients revealed hypermethylation of p14ARF (5/15 cases) and p16INK4a (1/15 cases) already at the stage of low-grade diffuse astrocytoma but consistent absence of homozygous deletions. These results suggest that aberrant p14ARF expression due to homozygous deletion or promoter hypermethylation is associated with the evolution of both primary and secondary glioblastomas, and that p14ARF promoter methylation is an early event in subset of astrocytomas that undergo malignant progression to secondary glioblastoma.
机译:染色体9p21上的CDKN2A基因座包含p14ARF和p16INK4a基因,在包括脑肿瘤在内的人类肿瘤中经常缺失。在这项研究中,我们筛选了从低度弥漫性星形细胞瘤发展而来的34例原发性(新生)胶质母细胞瘤和16例继发性胶质母细胞瘤,包括p14ARF和p16INK4a基因的改变,包括差异PCR的纯合缺失,甲基化特异性PCR的启动子高甲基化,和蛋白质表达的免疫组织化学。共有29个胶质母细胞瘤(58%)具有p14ARF纯合缺失或甲基化,而17个(34%)具有p16INK4a纯合缺失或甲基化。 13个胶质母细胞瘤显示p14ARF和p16INK4a纯合缺失,而9个仅显示p14ARF缺失。免疫组织化学显示在大多数胶质母细胞瘤(38 / 50,76%)中p14ARF表达的丧失,这与基因状态,即纯合缺失或启动子高甲基化有关。原发性和继发性胶质母细胞瘤之间的p14ARF和p16INK4a改变的总频率没有显着差异。对同一患者进行的多次活检分析表明,p14ARF(5/15例)和p16INK4a(1/15例)处于甲基化程度较低的弥漫性星形细胞瘤阶段,但始终没有纯合缺失。这些结果表明,由于纯合缺失或启动子高甲基化导致的异常p14ARF表达与原发性和继发性胶质母细胞瘤的进化有关,并且p14ARF启动子甲基化是星形细胞瘤中发生恶性进展为继发性胶质母细胞瘤的早期事件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号